secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0000950170-25-079009
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm shareholders approve 450,000 share increase to equity plan at annual meeting
--------------------------------------------------------------------------------

- Elected Garen G. Bohlin and Zhen Su as Class III directors with 3,066,819 and 3,191,845 votes for, respectively.
- Approved amendment to 2022 equity plan adding 450,000 shares; 2,606,928 for, 1,103,365 against, 344,880 abstain.
- Advisory vote on named executive officer compensation passed: 2,716,951 for, 1,041,611 against, 296,611 abstain.
- Advisory vote on say-on-pay frequency favored every year (3,263,514 votes); Board adopted annual frequency.
- Ratified Ernst & Young as independent auditor for FY2025: 6,237,926 for, 210,714 against, 115,566 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025079009/0000950170-25-079009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025079009/kpti-20250528.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-079009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer